Previous in vitro studies have shown conflicting evidence for the role of p53 in CDDP sensitivity of ovarian cancer cell lines and it is possible that there is a subset of p53 mutant tumours that are CDDP sensitive. The gene discussed is TP53; the disease is ovarian carcinoma.